AI MARKET SCANNING

BioNTech SE

📅 Next Catalyst: Nov 03, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -2.79%
MAX GAP RECORD -18.94%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $BNTX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 03, 2026 Earnings Release 2026-11-03 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 04, 2026 Earnings Release 2026-08-04 (BEFORE OPEN)
-3.54%
May 05, 2026 Earnings Release 2026-05-05 (BEFORE OPEN)
-3.60%
Mar 10, 2026 Earnings Release 2026-03-10 (BEFORE OPEN)
-18.94%
Nov 03, 2025 Earnings Release 2025-11-03 (BEFORE OPEN)
+0.86%
Aug 04, 2025 Earnings Release 2025-08-04 (BEFORE OPEN)
+4.71%
May 06, 2025 Earnings Release 2025-05-06 (BEFORE OPEN)
-0.29%
Mar 10, 2025 Earnings Release 2025-03-10 (BEFORE OPEN)
-2.77%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.5%
Bullish Gaps (2)
Bearish Gaps (8)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $BNTX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗